Skip to main content

Table 1 League table of the outcome of changes in monthly migraine days

From: Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials

hf-TMS-C3

              

*-8.70 (-10.41,-6.99)

0.03 (-8.74,8.80)

c-tDCS-CP4+a-tDCS-arm

-0.73 (-1.98,0.52)

            

*-8.73 (-12.44,-5.02)

-0.70 (-9.45,8.05)

-0.73 (-6.35,4.89)

c-tDCS-C4+a-tDCS-arm

            

*-8.00 (-11.66,-4.34)

-2.42 (-10.17,5.33)

-2.45 (-10.87,5.97)

-1.72 (-10.12,6.67)

hf-TMS-F3

-1.35 (-9.90,7.20)

          

-6.81 (-13.86,0.24)

-3.77 (-16.55,9.01)

-3.80 (-16.99,9.39)

-3.07 (-16.25,10.11)

-1.35 (-11.50,8.81)

single-hf-TMS-F3

           

-6.80 (-14.75,1.15)

-6.83 (-15.44,1.78)

-6.10 (-14.69,2.49)

-4.38 (-11.94,3.19)

-3.03 (-15.70,9.64)

a-tDCS-Oz+c-tDCS-Cz

         

*-1.90 (-2.27,-1.53)

-6.96 (-17.68,3.76)

-6.99 (-18.21,4.22)

-6.26 (-17.46,4.94)

-4.54 (-14.97,5.90)

-3.19 (-17.76,11.37)

-0.16 (-10.75,10.43)

c-tDCS-Oz+a-tCDS-Cz

        

-1.74 (-8.94,5.46)

-6.90 (-15.00,1.20)

-6.93 (-15.67,1.81)

-6.20 (-14.92,2.52)

-4.48 (-12.20,3.24)

-3.13 (-15.89,9.63)

-0.10 (-8.03,7.83)

0.06 (-10.64,10.76)

taVNS

       

*-1.80 (-3.38,-0.22)

-7.20 (-15.29,0.89)

-7.23 (-15.97,1.51)

-6.50 (-15.22,2.22)

-4.78 (-12.49,2.94)

-3.43 (-16.19,9.32)

-0.40 (-8.32,7.52)

-0.24 (-10.93,10.46)

-0.30 (-8.37,7.77)

PENS-Fp1Fp2

      

-1.50 (-3.05,0.05)

-7.49 (-18.00,3.02)

-7.52 (-18.53,3.50)

-6.79 (-17.78,4.21)

-5.06 (-15.28,5.16)

-3.72 (-18.13,10.69)

-0.69 (-11.06,9.69)

-0.52 (-13.15,12.10)

-0.59 (-11.08,9.90)

-0.29 (-10.77,10.20)

lf-tONS-Oz

  

0.00 (-7.72,7.72)

-0.17 (-8.20,7.86)

 

-1.21 (-8.10,5.67)

-7.36 (-15.45,0.73)

-7.39 (-16.13,1.35)

-6.66 (-15.38,2.06)

-4.94 (-12.65,2.78)

-3.59 (-16.35,9.16)

-0.56 (-8.48,7.36)

-0.40 (-11.09,10.30)

-0.46 (-8.53,7.61)

-0.16 (-8.22,7.90)

0.13 (-10.36,10.61)

STS-Afz

    

-1.34 (-2.89,0.21)

*-7.36 (-14.53,-0.20)

-7.39 (-15.28,0.49)

-6.66 (-14.53,1.20)

-4.94 (-11.52,1.64)

-3.59 (-15.70,8.51)

-0.56 (-7.53,6.41)

-0.40 (-10.41,9.61)

-0.46 (-7.60,6.67)

-0.16 (-7.29,6.97)

0.12 (-9.66,9.91)

-0.00 (-7.13,7.13)

Rt-nVNS

   

-0.71 (-2.06,0.64)

-7.49 (-18.42,3.45)

-7.52 (-18.93,3.90)

-6.79 (-18.19,4.62)

-5.06 (-15.72,5.59)

-3.72 (-18.44,11.00)

-0.69 (-11.49,10.12)

-0.52 (-13.50,12.45)

-0.59 (-11.50,10.33)

-0.29 (-11.19,10.62)

0.00 (-9.47,9.47)

-0.13 (-11.03,10.78)

-0.12 (-10.36,10.12)

hf-tONS-Oz

-0.17 (-8.75,8.40)

 

-1.21 (-8.72,6.30)

-7.66 (-18.81,3.49)

-7.69 (-19.32,3.94)

-6.96 (-18.57,4.65)

-5.24 (-16.12,5.64)

-3.89 (-18.77,10.99)

-0.86 (-11.88,10.17)

-0.70 (-13.86,12.46)

-0.76 (-11.89,10.37)

-0.46 (-11.59,10.67)

-0.17 (-9.90,9.55)

-0.30 (-11.43,10.83)

-0.30 (-10.77,10.17)

-0.17 (-10.35,10.00)

af-tONS-Oz

 

-1.04 (-8.87,6.79)

*-8.57 (-16.53,-0.61)

-8.60 (-17.21,0.01)

-7.87 (-16.46,0.72)

-6.15 (-13.72,1.43)

-4.80 (-17.47,7.87)

-1.77 (-9.55,6.01)

-1.61 (-12.20,8.99)

-1.67 (-9.60,6.26)

-1.37 (-9.30,6.56)

-1.08 (-11.46,9.30)

-1.21 (-9.14,6.72)

-1.21 (-8.18,5.77)

-1.08 (-11.89,9.73)

-0.91 (-11.94,10.12)

a-tDCS-C3+c-tDCS-Fp2

-0.13 (-0.63,0.37)

*-8.70 (-14.45,-2.95)

*-8.73 (-15.35,-2.11)

*-8.00 (-14.60,-1.40)

*-6.28 (-11.47,-1.08)

-4.93 (-16.34,6.48)

-1.90 (-7.40,3.60)

-1.74 (-10.79,7.31)

-1.80 (-7.51,3.91)

-1.50 (-7.20,4.20)

-1.21 (-10.01,7.59)

-1.34 (-7.04,4.36)

-1.34 (-5.62,2.94)

-1.21 (-10.51,8.09)

-1.04 (-10.60,8.52)

-0.13 (-5.64,5.38)

Sham/Control

  1. Pairwise (upper-right portion) and network (lower-left portion) meta-analysis results are presented as estimate effect sizes for the outcome of improvement of monthly migraine days. Interventions are reported in order of mean ranking of monthly migraine days improvement, and outcomes are expressed as mean difference (MD) (95% confidence intervals). For the pairwise meta-analyses, MD of less than 0 indicate that the treatment specified in the row got more improvement than that specified in the column. For the network meta-analysis (NMA), MD of less than 0 indicate that the treatment specified in the column got more improvement than that specified in the row. Bold results marked with * indicate statistical significance